Article Text

Download PDFPDF
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC
  1. C S L Lai1,
  2. C Boshoff1,
  3. M Falzon2,
  4. S M Lee2
  1. 1Wolfson Institute for Biomedical Research, University College London, London, UK
  2. 2University College Hospitals Trust, London, UK
  1. Correspondence to:
    Professor C Boshoff
    Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, UK; c.boshoff{at}ucl.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We report a case of a 55 year old Chinese female never smoker who presented with a 6 month history of cough in October 2002. In November 2002 she underwent a right middle lobectomy for adenocarcinoma. In June 2003 a CT scan showed recurrences in the mediastinum, pleura, and ribs. In January 2004 she completed six cycles of treatment with gemcitabine and carboplatin and the CT scan following treatment demonstrated a partial response. In June 2004 she developed breathlessness, unsteadiness, dizziness, and weakness involving the right upper limb. A CT scan showed disease recurrence in the chest with multiple …

View Full Text

Footnotes

  • This work was supported in part by the London Lung Cancer Group, London, UK (Registered Charity No. 1074994) which received funding from Roche to support research on erlotinib.

  • Competing interests: none.